On Tuesday, Novartis raised the prospect of divesting its generic drugs unit Sandoz while revising upwards its revenue estimate for its two best-selling pharmaceuticals. “Novartis has commenced a strategic review of the Sandoz Division. The review will explore all options, ranging… Read More ›
Profits and first quarter sales of Swiss drugmaker Novartis have met their 2020 targets following sales at its generics unit continuing through the coronavirus lockdown without disruptions its business. Novartis’ core net income rose to $3.55 billion, up from $2.8… Read More ›
Barbara Levi is currently the Group Legal Head, M&A and Strategic Transactions for Novartis. She will be joining Rio Tinto on January 1, 2020 and will be replacing Philip Richards who will be retiring from Rio Tinto on December 31,… Read More ›
Shareholders are scheduled to vote on Novartis’s planned spin-off of its Alcon eye care unit. On Thursday, at the annual general meeting of Swiss drugmaker Novartis, shareholders came in heavily at the drugmaker for the hike in drug prices. Novartis… Read More ›
Susanne Schaffert will be replacing Liz Barrett who will return to the U.S. to head a U.S. biotech firm. Swiss pharmaceutical giant Novartis has stated, it has appointed Susanne Schaffert, a veteran, as the head of its oncology business. She… Read More ›
The move is aimed at sharpening it focus on its prescription drugs business. On Friday, Novartis disclosed its plans of divesting all of its assets from its Alcon eye care devices business as it sharpens its focus on prescription drugs…. Read More ›
The acquisition will add AveXis top drug to its repertoire of drugs, which has a significant market in the U.S. for spinal muscular atrophy. On Monday, Switzerland-based healthcare giant Novartis announced its $8.7 billion deal to acquire AveXis; Novartis will… Read More ›
The elevation of key human resource personnel to Novartis’s board suggests that Vas Narasimhan is aiming to turn a new leaf at the Swiss pharmaceutical giant. Vas Narasimhan, Novartis’s new CEO is strategically changing the leadership in the Swiss drugmaker…. Read More ›
manageria.biz 